Adjunctive treatment with pramipexole for antipsychotic-induced hyperprolactinemia in patients with schizophrenia, Reserch for efficacy and tolerability.

Adjunctive treatment with pramipexole for antipsychotic-induced hyperprolactinemia in patients with schizophrenia, Reserch for efficacy and tolerability. - Adjunctive treatment with pramipexole for antipsychotic-induced hyperprolactinemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006556

Enrollment

Registered

2011-10-20

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

pramipexole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: schizophrenic patients who developed symptomatic hyperprolactinemia while taking antipsychotics

Exclusion criteria

Exclusion criteria: subjects were excluded if they had problems with thyroid function, renal function,liver function, gynecological problems, or other general illnesses.

Design outcomes

Primary

Measure	Time frame
serum prolactin level, Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026